Aclaris Therapeutics, Inc…announced that the U.S. Food and Drug Administration (the &#39;FDA&#39;) has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris

modzatinib (ATI-2138) - Aclaris

Aug 6, 2026